کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
1221295 | 1494654 | 2013 | 9 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Development and validation of a reversed phase liquid chromatographic method for analysis of griseofulvin and impurities Development and validation of a reversed phase liquid chromatographic method for analysis of griseofulvin and impurities](/preview/png/1221295.png)
A simple and robust reversed phase liquid chromatographic method was developed and validated for the quantitative determination of griseofulvin (GF) and its impurities in drug substances and drug products (tablets). Chromatographic separation was achieved on a Discovery C18 (250 mm × 4.6 mm, 5 μm) column kept at 30 °C. The mobile phase consisted of a gradient mixture of mobile phase A (water–0.1% formic acid pH 4.5, 80:20, v/v) and B (ACN–water–0.1% formic acid pH 4.5, 65:15:20, v/v/v) pumped at a flow rate of 1.0 mL/min. UV detection was performed at 290 nm. The method was validated for its robustness, sensitivity, precision, accuracy and linearity based on ICH guidelines. The robustness study was performed by means of an experimental design and multivariate analysis. Satisfactory results were obtained from the validation studies. The use of volatile mobile phases allowed for the identification of three main impurities present above the identification threshold using mass spectrometry (MS). The developed LC method has been applied for the assay and impurity determination of GF drug substances and tablets. The method could be very useful for the quality control of GF and its impurities in bulk and formulated dosage forms.
Figure optionsDownload as PowerPoint slideHighlights
► A new LC method for analysis of griseofulvin and impurities is described.
► Griseofulvin impurities were identified and characterized using ESI-MS/MS.
► Full factorial design was applied to investigate method robustness.
► LC method has been successfully applied for impurities determination.
Journal: Journal of Pharmaceutical and Biomedical Analysis - Volume 80, June 2013, Pages 9–17